Ideal JAK Inhibitor for Alopecia Areata: Baricitinib, Tofacitinib, Ritlecitinib, or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway

    January 2023 in “ Indian Dermatology Online Journal ”
    Kabir Sardana, Savitha Bathula, Ananta Khurana
    Studysummary This review discusses the role of the JAK/STAT pathway in managing alopecia areata and emphasizes the need for further research to determine the ideal JAK inhibitor, as it reports no new clinical results.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on journals.lww.com →
    Discuss this study in the Community →

    Research cited in this study 28

    1. Induction of T Cell Exhaustion by JAK1/3 Inhibition in the Treatment of Alopecia Areata Frontiers in immunology · 2022
    2. Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study Frontiers in Medicine · 2022
    3. Systematic Review: Alopecia Areata and Tofacitinib in Pediatric Patients Cutaneous and Ocular Toxicology · 2022
    4. Two Phase 3 Trials of Baricitinib for Alopecia Areata The New England Journal of Medicine · 2022
    5. Ritlecitinib And Brepocitinib Demonstrate Significant Improvement In Scalp Alopecia Areata Biomarkers ˆThe ‰journal of allergy and clinical immunology/Journal of allergy and clinical immunology/˜The œjournal of allergy and clinical immunology · 2021
    6. A Comprehensive Literature Review of JAK Inhibitors in the Treatment of Alopecia Areata Clinical, cosmetic and investigational dermatology · 2021
    7. Selective Inhibition of JAK3 Signaling Is Sufficient to Reverse Alopecia Areata JCI insight · 2021
    8. A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results Journal of the American Academy of Dermatology · 2021
    9. Experience with Oral Tofacitinib in Severe Alopecia Areata with Different Clinical Responses Journal of Cosmetic Dermatology · 2021
    10. Alopecia Areata Is Characterized by Dysregulation in Systemic Type 17 and Type 2 Cytokines, Which May Contribute to Disease-Associated Psychological Morbidity British journal of dermatology/British journal of dermatology, Supplement · 2019
    11. JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2019
    12. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study Dermatology · 2018
    13. High-Throughput T Cell Receptor Sequencing Identifies Clonally Expanded CD8+ T Cell Populations in Alopecia Areata JCI insight · 2018
    14. JAK Inhibitors for Treatment of Alopecia Areata ˜The œjournal of investigative dermatology/Journal of investigative dermatology · 2018
    15. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis Journal of Investigative Dermatology · 2018
    16. Comparison of the Treatment Outcome of Oral Tofacitinib with Other Conventional Therapies in Refractory Alopecia Totalis and Universalis: A Retrospective Study Acta dermato-venereologica · 2018
    17. Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents Journal of Investigative Dermatology Symposium Proceedings · 2017
    18. Oral Tofacitinib Monotherapy in Korean Patients with Refractory Moderate-to-Severe Alopecia Areata: A Case Series Journal of the American Academy of Dermatology · 2017
    19. Efficacy of Topical Tofacitinib in Promoting Hair Growth in Non-Scarring Alopecia: Possible Mechanism via VEGF Induction Archives of Dermatological Research · 2017
    20. Brazilian Experience of Treating Alopecia Universalis with Novel Antirheumatic Therapy Tofacitinib: A Case Series Rheumatology and Therapy · 2017
    21. Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata JCI insight · 2016
    22. Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata JCI insight · 2016
    23. Familial Aggregation of Alopecia Areata Journal of the American Academy of Dermatology · 2016
    24. Pharmacologic Inhibition of JAK-STAT Signaling Promotes Hair Growth Science Advances · 2015
    25. The Role of Lymphocytes in the Development and Treatment of Alopecia Areata Expert Review of Clinical Immunology · 2015
    26. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014
    27. Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis Journal of Investigative Dermatology · 2014
    28. Genome-Wide Association Study in Alopecia Areata Implicates Both Innate and Adaptive Immunity Nature · 2010

    Related research 9

    1. Efficacy of Janus Kinase Inhibitors in Adult Patients With Alopecia Areata International journal of research in dermatology · 2023
    2. Ideal JAK Inhibitor for Alopecia Areata: Baricitinib, Tofacitinib, Ritlecitinib, or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway Indian Dermatology Online Journal · 2023
    3. Clinical Response to Adjunctive Platelet-Rich Plasma Injections in a Patient with Alopecia Universalis on Oral Tofacitinib JAAD case reports · 2021
    4. Topical Tofacitinib in Treatment of Alopecia Areata Einstein (São Paulo) · 2020
    5. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study Dermatology · 2018
    6. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib PubMed · 2018
    7. Tofacitinib 2% Ointment, a Topical Janus Kinase Inhibitor, for the Treatment of Alopecia Areata: A Pilot Study of 10 Patients Journal of the American Academy of Dermatology · 2017
    8. A Case of Topical Ruxolitinib Treatment Failure in Alopecia Areata Journal of cutaneous medicine and surgery · 2017
    9. Transient Efficacy of Tofacitinib in Alopecia Areata Universalis Case Reports in Dermatology · 2016